MENLO PARK, Calif.--(BUSINESS WIRE)--
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO, will present at the Jefferies Healthcare Conference.
Details of the event are as follows:
Jefferies Healthcare Conference, June 7-9, 2023 in New York, NY.
- Eric Easom, Co-Founder, President and CEO, will provide a corporate overview on Thursday, June 8, at 4:30 p.m. ET.
A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at . An archived replay will be available for at least 30 days following the presentation.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our initial candidate is epetraborole, which we are studying as a once-daily, oral treatment with a novel mechanism of action for patients with nontuberculous mycobacteria (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria that leads to irreversible lung damage and can be fatal. For more information, please visit our website at .
View source version on businesswire.com:
